International Journal for Parasitology: Drugs and Drug Resistance

Large-scale treatment with praziquantel (PZQ) monotherapy is used to control schistosomiasis, leading to concerns about the emergence of PZQ-resistance. In Western Kenya, schistosome-infected patients frequently remain egg-positive following PZQ treatment, and several "hotspot" villages have been observed where transmission remains high, despite annual mass PZQ treatments. This project asks (i) whether PZQ-resistant parasites are found in Western Kenya and (ii) whether "hotspot" villages can be explained by a higher prevalence of PZQ-resistant parasites. We established a simple platform for directly assaying worm motility following in vitro PZQ-exposure in adult schistosomes isolated from a field setting. To do this, we established snail and hamster breeding colonies, and generated large populations of field-derived adult worms, by (i) harvesting S. mansoni eggs from multiple infected patients; (ii) infecting Biomphalaria spp snails with miracidia; (iii) infecting hamsters with released cercariae; (iv) perfusing adult worms from hamsters, and (iv) examining drug response following exposure to PZQ (1 {micro}g/ml for 1 day) in individual S. mansoni worms using an automated movement assay. We measured PZQ-response in 1,800 adult male parasites, representing an estimated 185 parasite genotypes. We identified a single worm that remained motile after PZQ-exposure among the 185 parasite genotypes surveyed (frequency = 0.54%; 95% CI 0.01 - 2.97%, exact binomial) consistent with PZQ-resistant worms being extremely rare or absent. Our direct phenotypic screening results suggests that (i) PZQ-resistance is not currently an obstacle for S. mansoni control in Western Kenya, and (ii) that other factors explain the existence of persistent hotspots.

Microsporidia are obligate intracellular parasites that infect diverse animals. Budding yeast has long been used to define core molecular pathways and inhibitors that target them. To test whether these compounds can target conserved pathways in the microsporidian Nematocida parisii, we assessed 15 inhibitors with defined yeast targets that had not previously been tested for effects on infection of Caenorhabditis elegans. Most showed little activity against N. parisii, except tunicamycin. These results identify tunicamycin as a potential tool for studying endoplasmic reticulum stress in microsporidia, while indicating that most yeast-targeted inhibitors are largely ineffective in this system.

Cryptosporin, a fungal metabolite, exhibited potent antimalarial activity against both asexual blood stage Plasmodium falciparum and liver-stage Plasmodium berghei with minimal human HepG2 toxicity. Unlike atovaquone, cryptosporins mechanism is independent of mitochondrial electron transport. Minimum inoculum of resistance showed a low risk of resistance development. RNA-Seq analysis revealed the upregulation of genes associated with sexual development including many canonical markers such as Pfs25, and PfCCp3, suggesting a stress response that is also seen when parasites are treated with artemisinin. In vitro evolution and whole genome sequencing analysis identified a mutation (F138Y) in PfAQP (PF3D7_1132800) and duplications of the two superoxide dismutase genes, PfSOD-1 (PF3D7_0814900) and PfSOD-2 (PF3D7_0623500). CRISPR/Cas9 editing confirmed that the F138Y mutation in PfAQP was sufficient to confer resistance to cryptosporin. Alignment of the P. falciparum structure with that of HsAQP3 suggests the mutation may impact transport of hydrogen peroxide and the transition between open and closed conformations. Indeed, studies with BY4742 {Delta}fps1 yeast expressing PfAQP showed that the permeability of PfAQP was not affected by cryptosporin and that it is likely not a direct target. Taken together, this study highlights the role of PfAQP in the resistance development of cryptosporin. In addition, cryptosporin likely induces high levels of oxidative stress which results in the duplications of oxidative dismutase genes as part of the parasites defense response. These findings highlight the role of PfAQP in mediating drug resistance, the mechanism of which warrants further research.

Insecticide-based vector control remains the cornerstone of malaria prevention, averting approximately 1.2 billion cases between 2000 and 2025. These interventions primarily reduce transmission by killing mosquitoes; however, widespread reliance on a limited number of compounds has driven the emergence of insecticide resistance. This has prompted the development of new insecticides with novel modes of action. Notably, the pyrrole insecticide chlorfenapyr has been shown to affect both the mosquito vector and the malaria parasite, suggesting that compounds with dual activity could provide an additional strategy to suppress transmission. Here, we present a medium-throughput discovery pipeline that integrates in vitro Plasmodium sporozoite motility assays with machine-learning-based analysis, alongside in vivo exposure of infected Anopheles mosquitoes and quantification of parasite development. Screening 32 insecticidal chemistries identified five compounds that significantly impaired sporozoite motility, including three avermectin endectocides, the mitochondrial complex III inhibitor hydramethylnon, and tralopyril, the active form of chlorfenapyr. Several compounds transiently increased motility, indicating that parasite physiology is frequently influenced by insecticide exposure. In vivo exposure to abamectin reduced parasite numbers in both the haemolymph and salivary glands and impaired productive motility. Importantly, this inhibition was confirmed in Plasmodium falciparum-infected mosquitoes, where exposure significantly reduced salivary gland invasion. These findings reveal that parasite-directed activity among insecticides may be more common than previously appreciated and demonstrate a scalable approach to identify compounds capable of simultaneously killing mosquitoes and suppressing parasite transmission. Significance StatementVector control relies heavily on insecticides that kill mosquitoes, yet rising resistance threatens their effectiveness. Here we show that several insecticides also affect the malaria parasite itself. Using a scalable screening pipeline combining machine learning-assisted sporozoite motility analysis with mosquito infection assays, we found that 15% of tested insecticides significantly impaired parasite motility, including compounds with distinct modes of action. Among these hits, the avermectin abamectin reduced parasite dissemination in mosquitoes and limited salivary gland invasion in both Plasmodium berghei and the human malaria parasite P. falciparum. These findings reveal that parasite-directed activity among insecticides may be more widespread than expected and highlight the potential to develop vector control tools that simultaneously kill mosquitoes and block parasite transmission.

Fasciola hepatica is a trematode parasite responsible for fasciolosis, a liver disease that affects humans and livestock worldwide. Together with other food-borne trematode infections, fasciolosis is considered a neglected tropical disease. Further, it imposes substantial agricultural losses due to infections in ruminants. No vaccine is currently available, and control heavily relies on drug treatment, especially with triclabendazole (TCBZ). However, the intensive use of TCBZ over the past four decades has led to increasing rates of treatment failures and the emergence of drug-resistant parasites. Therefore, the identification of new treatment options is an urgent priority. The currently available toolset for drug screening, however, is limited. To address this need, we established a novel, semi-automated, standardized, and objective screening assay based on motility monitoring of newly excysted juveniles using microscopic live imaging. The assay was validated by testing a panel of ten compounds with known anthelmintic properties, amongst them TCBZ (IC50: 1.5 {micro}M) and the new activator of the F. hepatica transient receptor potential melastatin (TRPM) ion channel, benzamidoquinazolinone (IC50: 1.05 {micro}M). In addition to these two compounds with known activity against F. hepatica, three compounds were identified as particularly promising with a fast onset of action and IC50 values in the nanomolar range: the salicylanilides MMV665807 (IC50: 44 nM), niclosamide (IC50: 32 nM), and its ethanolamine salt, niclosamide ethanolamine (IC50: 9 nM). Complementary live/dead staining revealed that only TCBZ displayed parasiticidal activity, while the other compounds, although leading to parasite paralysis, did not lead to parasite death within 72 hours. Scanning electron microscopy of drug treated parasites did not reveal any significant damage at concentrations corresponding to the IC50s, but strong phenotypes were visible at 20 {micro}M. The presented motility assay provides a robust method for the discovery of novel anthelmintic compounds and facilitates the ongoing effort to combat fasciolosis. Author SummaryFasciola hepatica, the common liver fluke, is a parasitic platyhelminth that infects the liver and biliary ducts of humans and livestock, causing fasciolosis, a Neglected Tropical Disease as defined by the World Health Organization. Triclabendazole is the drug of choice to treat humans and animals. However, its intensive use has led to the emergence of drug resistance resulting in treatment failures worldwide. The identification of novel drugs is therefore urgent. Here, we present a semi-automated and objective method to assess the activity of compounds on one of the key life stages of the parasite: the newly excysted juveniles (NEJ). This stage is highly motile and motility assessment can be exploited to screen for bioactive compounds. Using time-lapse imaging, we quantified NEJ movement after drug exposure. From a panel of ten tested reference anthelmintics, two known fasciolicides (triclabendazole and benzamidoquinazolinone) and three additional compounds (MMV665807, niclosamide, and niclosamide ethanolamine) displayed particularly strong activity and were selected for further investigation. This method represents a robust tool for drug screening and facilitates the discovery of new compounds against F. hepatica.

Short-chain dehydrogenases/reductases (SDRs) constitute a large enzyme superfamily involved in endogenous metabolism and xenobiotic biotransformation. In the parasitic nematode Haemonchus contortus, SDRs may catalyze the carbonyl reduction of a benzimidazole anthelmintic flubendazole (FLU), whose increased reduction is associated with FLU resistance. This study thus investigated the constitutive expression of SDRs and their inducibility by FLU in drug-susceptible and benzimidazole-resistant strains of H. contortus. The expression of 23 sdr genes was analyzed by quantitative PCR, while targeted proteomic assays enabled the quantification of 15 SDR proteins. In adult nematodes, pronounced sex-dependent differences were detected at both transcript and protein levels. Resistance-associated alterations were less pronounced and were observed predominantly in males, with SDR9, SDR12, SDR15, and SDR20 displaying increased protein abundances in the resistant strain. Exposure to FLU induced only minimal transcriptional responses in juvenile stages, whereas adult nematodes exhibited marked sex- and strain-specific responses in the expression of SDRs. The strongest transcriptional effects were detected in resistant males, while significant protein-level changes following FLU treatment were observed exclusively in adults of the drug-susceptible strain. Notably, SDR9 and SDR20 combined resistance-associated expression patterns with responsiveness to FLU exposure. Taking together, the first targeted proteomic characterization of SDRs in H. contortus revealed several SDR isozymes with constitutive overexpression in resistant nematodes and/or inducibility by FLU, suggesting a potential role in adaptation to anthelmintic exposure.

Malaria, of which the most virulent form is caused by Plasmodium falciparum parasites, remains a major global health burden. The appearance of resistance to first line treatments artemisinin-based therapies, emphasizes the need to identify new parasite vulnerabilities to develop new therapeutics. Phosphoinositides are central regulators of membrane identity, vesicular trafficking, and signaling, and their synthesis depends on tightly controlled phosphatidylinositol transfer by Sec14-like phosphatidylinositol transfer proteins in many eukaryotes, yet their roles in P. falciparum remain poorly defined. Here, we analyzed six P. falciparum Sec14 domain-containing proteins: PfSec14-1 (PF3D7_0626400), PfSec14-2 (PF3D7_0629900), PfSec14-3 (PF3D7_0717100), PfSec14-4 (PF3D7_0920700), PfSec14-5 (PF3D7_1007200), and PfSec14-6 (PF3D7_1127600). Domain organization segregates these proteins into a BNIP-2 and Cdc42GAP homology (BCH) subfamily (PfSec14-3, PfSec14-5) and a canonical Sec14 subfamily (PfSec14-1, PfSec14-2, PfSec14-4, PfSec14-6). Yeast complementation assays showed that PfSec14-1, PfSec14-4, and PfSec14-6 partially rescue growth of a temperature-sensitive sec14 mutant, suggesting phosphatidylinositol and phosphatidylcholine transfer activity. Gene disruption revealed that PfSec14-1 is important for asexual blood-stage proliferation, whereas PfSec14-2 is dispensable under standard culture conditions. In contrast, mislocalization of PfSec14-1 and PfSec14-4 using a knock-sideways approach did not impair asexual growth. Subcellular localization indicates distinct distributions for PfSec14-1, PfSec14-2, and PfSec14-4. Together, these findings reveal functional and spatial diversification of Sec14-like phosphatidylinositol transfer proteins in P. falciparum.

Adhesion interactions between Plasmodium falciparum infected erythrocytes (IEs) and human cells bring about microvascular sequestration and contribute to severe malaria pathology. Parasite adhesion molecules on the IE surface are members of the P. falciparum erythrocyte membrane protein 1 (PfEMP1) family, encoded by var genes, which interact with receptors on human cells. Progress in understanding PfEMP1-host receptor interaction is hindered by the lack of genetic tools for PfEMP1 functional studies in live parasites and the spontaneous switching of var gene transcription in culture leading to change in adhesion phenotype. We developed a CRISPR/Cas9 genome editing strategy that takes advantage of var gene mutually exclusive expression to generate single variant P. falciparum lines and enable reverse genetic studies of PfEMP1 function. A drug resistance gene and 2A peptide enabling bi-cistronic transcription were inserted between the promoter and exon I of the it4var60 gene encoding a PfEMP1 variant that mediates the virulence-associated rosetting phenotype. After genome editing and drug selection, only it4var60-transcribing parasites survived, and >90% of IEs expressed IT4VAR60-PfEMP1 on their surface and formed rosettes. When drug pressure was removed, switching to other variants occurred. The approach was adapted to generate epitope tagged-PfEMP1 allowing immunofluorescent detection with commercial antibodies, and modifications of the homology directed repair template enabled investigation of PfEMP1 function including point mutations and a gene knockout that abolished adhesion. These methods can be applied to any var gene in any P. falciparum genotype and are potentially transformative for functional studies of multi-gene family members in live parasites.

Beef cattle farming plays a crucial role in the livestock-related economies of both Italy and Argentina. Although both countries have grazing systems of meat production, the heterogeneity of those systems leads to different parasitological scenarios regarding epidemiology and the presence of resistance to commonly used anthelmintic drugs. Considering ivermectin (IVM) is the most widely used anthelmintic for treating gastrointestinal nematode (GIN) infections in cattle, the current studies evaluated the efficacy of ivermectin (IVM) given subcutaneously (SC) to both young calves and adult cows in ten (10) commercial cattle farms from Italy (A to E) and Argentina (F to J). The work was complemented with the assessment of the IVM plasma exposure and disposition kinetics both in young and adult animals. While adult cows and young calves were included in the study performed in Italy (Campania region), only calves aged 8-14 months old were selected to perform the efficacy trials in Argentina (central area of the Buenos Aires province). Fifteen (15) calves/cows naturally infected with GINs were treated with IVM (0.2 mg/kg) in each of the Farms. The therapeutic response (efficacy) was determined at 14 days after treatment by the faecal egg count reduction test. Six (6) adult cows and eight (8) young calves treated with IVM were randomly selected to perform the pharmacokinetic (PK) study with blood samples being taken 2 h and 21 days post-treatment. Drug concentrations were measured by HPLC. Similar IVM PK trends were obtained for both adult and young cattle. The IVM systemic exposure (expressed as AUC) obtained for adult cattle (380{+/-}158 ng.d/mL) was similar to that observed in calves group (313{+/-}85.5 ng.d/mL). No statistical differences between animals from both ages were observed for the most representative PK parameters (P>0.05). Surprisingly, while in Argentina IVM resistance was present in all the farms evaluated (90% CI = 0%-95%), in Italy a fully susceptible nematode population was presented in three farms (90% CI = 96%-100%) and only a very low level of IVM resistance was detected in the rest of the farms (90% CI = 92%-98%). Whereas Cooperia spp. and Haemonchus spp. were identified as the principal genera exhibiting resistance to IVM in Argentina, Cooperia spp., Ostertagia spp., and Oesophagostomum spp. were reported to display low levels of resistance under the Italian field scenario. In conclusion, IVM can be safely and effectively used in both young and adult cattle with similar disposition kinetic patterns. While its therapeutic response is failing under the conditions investigated in the Argentinian farms, its efficacy remains notably high in the Italian region under study. However, the use of IVM, as well any other active antiparasitic principle, should always be preceded by a diagnostic assessment of the nematode populations resistance status.

Anthelmintic drugs are used to control soil-transmitted helminths that infect a third of the worlds human population. There is increasing concern about the development of resistance to anthelmintic drugs because of the limited number of compounds available and there is an unmet need for new resistance-busting drugs. Here we describe the presence of a previously unrecognized endogenous acetylcholine analogue, {beta}-alanine betaine, which may serve as an endogenous ligand for an alternate subfamily of nicotinic receptors (DEG-3/DES-2) that could be developed as novel drug targets because their analogues are not present in their human or animal hosts. We collected peri-enteric fluid from female Ascaris suum (a model for the human parasite, Ascaris lumbricoides) and subjected it to chromatography and MS/MS to reveal signals consistent with acetylcholine, choline, and {beta}-alanine betaine but we did not recover betaine. We injected betaine into female Ascaris suum which produced no effect. However, injection of {beta}-alanine betaine, produced characteristic pretzel coiling and injection of levamisole produced a rod-like spastic paralysis. The differences between {beta}-alanine betaine and levamisole suggested that they activate different nAChRs subfamilies. PCR showed that messages of the DEG-3 subfamily of nAChR channels, which are betaine targets and were present in the intestine and body wall of A. suum. Calcium signaling experiments showed that {beta}-alanine betaine increased intracellular calcium of the intestine enterocytes and electrophysiology of the body muscle cells demonstrated that {beta}-alanine betaine produced membrane potential depolarization. In N2 elegans, application of {beta}-alanine betaine produced gradual inhibition of motility, which was reduced in acr-20, acr-23, des-2, deg-3 and lgc-41 null-mutants. These observations suggest that, in addition to acetylcholine, {beta}-alanine betaine - an anaerobic analog of betaine - may function as an endogenous ligand in anaerobic nematodes such as A. suum. An expanded repertoire of nicotinic acetylcholine receptor subfamilies in nematodes relative to mammals may reflect a corresponding need for diversification of cholinergic endogenous ligands in these organisms. This repertoire could allow their simpler neuronal system to perform more complex controls and be exploited for development of different and novel subfamily selective cholinergic anthelmintics.

Antimalarial drug resistance remains one of the most significant challenges to global malaria control. The emergence of resistance to chloroquine, the first truly globally distributed antimalarial, has been extensively studied but is still not fully understood. While mutations in the Plasmodium falciparum chloroquine resistance transporter (PfCRT) primarily drive resistance, the phenotype is complex and multigenic, with mutations in the putative amino acid transporter PfAAT1 recently confirmed to play a modulatory role. To date studies have focused on PfAAT1 mutations found in African and Southeast Asian P. falciparum lineages, but chloroquine resistance emerged independently in South America, where there may be novel PfAAT1 polymorphisms that are functionally important. We used AlphaFold modelling to reveal high homology between PfAAT1 and the human lysosomal arginine transporter SLC38A9, which allows prediction of membrane orientation and identifies a partially open channel accessible from the cytoplasm. Several PfAAT1 mutations found only in South American isolates sit near the entrance of this pore, most notably V231 where mutation to aspartate is predicted to alter channel conformation and influence transport, while nearby P446A (which is always found in combination with V231D) and I248T are predicted to impact pore flexibility and local structural stability. To functionally validate these insights, we employed CRISPR/Cas9 gene editing across parasite strains with diverse geographic origins. Reverting the regional V231D mutation in the South American 7G8 strain significantly reduced CQ resistance, providing the first functional evidence that this residue modulates drug susceptibility. Furthermore, introducing the apparently Colombia-specific I248T mutation significantly enhanced parasite multiplication rates in 7G8, demonstrating complex fitness and sensitivity trade-offs. Our findings reinforce the distinct evolutionary trajectory for South American CQ resistance and highlight the necessity of including additional pfaat1 mutations in global molecular surveillance strategies. Author SummaryAntimalarial drug resistance is a major threat to global public health. Chloroquine was used widely in the 1950s-60s as part of a global malaria eradication campaign, but resistance emerged in multiple places independently and chloroquine resistant parasites directly led to the death of millions of children. Chloroquine resistance is primarily driven by mutations in the transporter PfCRT which are thought to increase export of chloroquine from the digestive vacuole, where chloroquine acts to prevent the ability of the parasite to digest haemoglobin as a source of energy. However, it is becoming increasingly clear that additional vacuolar transporters can also modulate chloroquine resistance. In this study we focused on mutations in the putative amino acid transporter 1 (PfAAT1) which are specific to South America, where chloroquine resistance emerged independently from Southeast Asia. By integrating AlphaFold structural predictions with CRISPR/Cas9 gene editing across geographically diverse parasite backgrounds we provide the first functional evidence that the region-specific V231D mutation significantly diminishes chloroquine resistance. These findings emphasise that chloroquine resistance in South America followed a unique trajectory and that PfAAT1 is involved in complex fitness and sensitivity trade-offs. This work emphasises the benefits of integrating diverse experimental and modelling approaches with global molecular surveillance.

Neoparameoba perurans causes Amoebic Gill Disease (AGD), a major parasitic disease of marine-phase Atlantic salmon and rainbow trout worldwide. Treatment options are limited to freshwater baths, which are costly at scale and exhibit only limited long-term efficacy. N. perurans contains an obligate eukaryotic symbiont, Perkinsela-like organism (PLO). PLO belongs to the class Kinetoplastida, which includes medically and veterinary important parasites such as Trypanosoma and Leishmania. As such, we hypothesised that trypanocidal drugs developed against other kinetoplastids might also affect N. perurans, potentially through disruption of its PLO symbiont, and used this hypothesis as a rationale for prioritising a focused panel of candidate compounds for screening. A holographic motility-based cytotoxicity assay was established to identify promising candidates in vitro, followed by controlled host tolerance testing and finally a field efficacy sea trial using naturally AGD-exposed site in the west of Ireland. Several compounds showed activity in vitro, especially miltefosine (EC50 1.84 uM, amoebicidal) and isometamidum (EC50 4.63 uM, amoebostatic). In vivo (two intramuscular injections, two weeks apart), miltefosine (Odds Ratio (OR) 0.62), isometamidum (OR 0.61) and benznidazole (OR 0.64) significantly improved gill score over four weeks, with miltefosine showing the largest effect size. Gill parasitaemia, measured via qPCR, was not reduced. Instead, two compounds increased apparent amoeba loads. This work support trypanocidal as potential AGD treatments in the field, although optimisation of dosing, delivery and mode of action requires further study.

BackgroundPlasmodium falciparum field isolates exhibit genomic variation, including copy number variation and sequence divergence. In contrast, the P. falciparum 3D7 reference genome (Pf3D7) was derived from a long-term laboratory-adapted strain and does not fully reflect the genomic variation among field isolates. The extent to which the reference genome influences RNA-seq mapping and expression inference in natural infections remains unclear. ResultsWe generated both a reference genome and single cell RNA sequencing (scRNAseq) data from a P. falciparum-infected carrier in Mali. This new ML52 assembly was annotated using Companion with Pf3D7 as the reference. scRNAseq reads from the natural infection isolate were aligned to both the Pf3D7 genome and the isolate-specific ML52 genome, followed by locus-level alignment inspection. For most conserved genes, expression inference was concordant for both references, while genes showing reference-genome-dependent differences were investigated further. Some discrepancies were attributed to mapping artefacts or to reads aligning to unplaced genomic contigs that reflected divergent haplotypes from the co-infecting strains in the naturally infected carrier. While most multigene family loci showed concordant gene expression across both references, var genes exhibited considerable mis-mapping against 3D7 var loci as well as 2/3 of var reads not mapping at all to 3D7. ConclusionscRNAseq expression inference in P. falciparum is robust for conserved genes and most multigene families when comparing to a matched vs unmatched reference genome, but the extremely polymorphic var genes require a matched assembly in order to evaluate expression. These findings highlight the importance of the reference genome for var gene studies and should be considered when interpreting transcriptomic analyses in other organisms possessing highly variable antigenic loci.

Over a quarter of the worlds population is at risk of infection by soil transmitted helminths (STH). Among the STHs Trichuris trichiura infects approximately 7% of people globally, causing a loss of 232,000 DALYS. The main strategy to combat T. trichiura infection focusses on mass drug administration with the benzimidazoles. Whilst albendazole and mebendazole have been effective at reducing the burden of other STHs, the cure rate for whipworm is less than 50% with resistance alleles rising. Glucose is the most studied nutrient in Trichuris spp, however we have no understanding, at the molecular level of the mechanism of uptake in Trichuris spp. We sought to identify putative glucose transporters in Trichuris and investigate how these can be inhibited with phloretin. Using the C. elegans Facilitated Glucose Transporter 1 (FGT) sequence we identified two potential homologs in T. muris (TmGLT) and T. trichiura (TtGLT). We should both proteins contained sequence similarity to FGT1 and contained multiple sequence domains associated with glucose and sugar transport. Further, using Alphafold and molecular docking we show glucose docking sites consistent with transport. To asses the ability of phloretin to inhibit glucose transport, we also performed molecular docking with phloretin, showing possible inhibition. To validate the potential inhibition in vitro we measured the 48h LC50 of phloretin which we showed to be 111 ug/ml against adult T. muris worms, around half that of mebendazole in the same conditions. In contrast phloretin exhibited no effect on worm burden or fecundity in vivo. Together these findings provide the first in silico characterisation of putative glucose transporters in Trichuris spp and have identified glucose transport inhibition as a promising avenue for anthelminthic drug discovery. Whilst further work is required to optimise in vivo efficacy, our results highlight parasite glucose acquisition pathways as potential druggable targets in whipworm.

Drug repositioning has emerged as an attractive strategy to accelerate the development of new antimalarial therapies, particularly by evaluating compounds already used against pathologies co-endemic with malaria. This approach offers the advantage of leveraging existing pharmacokinetic, toxicological, and safety data, thereby potentially shortening the drug development pipeline. However, transposing a compound from its original therapeutic indication to an antimalarial use is far from straightforward: differences in target biology, parasite stage specificity, pharmacodynamic requirements, and host-parasite interactions can result in a loss of efficacy despite promising in vitro or structural rationale. Rigorous in vivo validation therefore remains indispensable before any repositioning hypothesis can be considered translationally relevant. In this context, we evaluated the blood-stage antimalarial activity of triclabendazole, an antihelminthic drug used against co-endemic fascioliasis, together with its metabolite triclabendazole sulfoxide, and sutezolide, an oxazolidinone antibiotic, in a murine model of Plasmodium berghei ANKA infection following oral administration. None of the three compounds demonstrated significant antimalarial activity under these experimental conditions, contradicting a previously published repositioning hypothesis. Beyond these specific findings, our study is deliberately framed within the 3Rs principles (Replacement, Reduction, Refinement) governing animal experimentation. We argue that publishing negative in vivo results is not only scientifically legitimate but ethically necessary: sharing such data allows research teams working on similar preclinical models to build on existing knowledge, avoid unnecessary experimental duplication, and ultimately reduce the number of animal procedures performed across the field. We advocate for wider dissemination of negative outcomes in antimalarial drug repositioning research as a concrete contribution to more responsible and efficient use of animal models in preclinical pharmacology. Graphical Abstract

Mass drug administration (MDA) using Praziquantel is central to efforts to eliminate Schistosomiasis. However, regions which respond poorly to MDA ("persistent hotspots") have been reported in many regions of Africa, including in Western Kenya. One possible explanation for persistent hotspots is that these areas contain PZQ resistant schistosome parasites. Recent studies have shown that Sm.TRPMPZQ gene is the molecular target for PZQ in schistosome parasites and that mutations in this gene can result in PZQ resistance. This study characterized mutations within Sm.TRPMPZQ in 23,420 miracidia collected from both hotspot and non-hotspot villages in Siaya County, western Kenya. We collected triplicate pools of 780.67 (SD {+/-} 183.47) miracidia from 135 people in five hotspot villages, where S. mansoni prevalence remains high despite over 5 annual treatments, and from 62 people from 5 non-hotspots villages where annual treatment resulted in reduction in prevalence. We extracted DNA from each miracidia pool, amplified 15 amplicons covering 1,695bp of the Sm.TRPMPZQtransmembrane domain and sequenced these to high read depth (21,110x) using a Miseq at KEMRI-CGHR. We identified five high confidence (frequency [≥] 0.01) Sm.TRPMPZQ variants. These included four synonymous changes and a non-synonymous variant (p.L1476I). p.L1476I is found at similar frequency in non-hotspot (0.040 {+/-} 0.006) and hotspot villages (0.044 {+/-} 0.0050) (Mann Whitney U=18, p= 0.31) and does not impact PZQ-response in Ca2+ reporter assays. Our studies show that resistance variants in Sm.TRPMPZQ are rare or non-existent in the locations studied and do not explain the existence of hotspots in this region.

Laboratory models are invaluable tools for studying parasite biology and pathogenesis, especially for helminth infections. However, the complex life cycles and frequently narrow host specificity of helminths present challenges to maintaining access to critical parasite material in a laboratory setting. This is especially true of Necator americanus, the most common species of hookworm that infects humans globally. Here we report the successful laboratory adaptation of an African strain of N. americanus, originally isolated from infected individuals in Beposo, Ghana. The Beposo strain has been successfully passaged across 9 generations in Golden Syrian hamsters maintained on oral dexamethasone. Differential susceptibility to mebendazole and albendazole was evaluated using an egg hatch assay, and DNA sequencing of the beta-tubulin isotype 1 gene did not identify known resistance-associated mutations in the endemic strain. Sequencing of the mitochondrial COX1 gene revealed that specimens of N. americanus from Ghana, along with reported sequences from Togo, are distinct from those from South America and Asia. Complementary microsatellite-based population analysis revealed substantial genetic variation in the founding parasite population. To further characterize the novel Beposo strain, a draft hybrid genome assembly was generated from genomic DNA extracted from a single adult male worm via an optimized Oxford Nanopore Technologies MinION library preparation approach tailored to low-input sample types. This high-quality assembly, including a complete mitogenome, is 202.8Mb in 950 contigs with an N50 >449 kb. It contains >95% of conserved nematode orthologs in complete single copy and is estimated by homology-based gene prediction to contain 12,804 genes. This study represents the first comprehensive characterization of a strain of N. americanus originating in Africa that has been successfully adapted to a laboratory animal model.

Malaria parasite virulence will be impacted by naturally occurring variation in multiplication rates. Clinical isolates of Plasmodium falciparum exhibit a range of multiplication rates under exponential growth conditions in culture, but it needs to be discovered if relative multiplication rates under competitive conditions are principally defined by this underlying multiplication rate potential. Relative multiplication rates of P. falciparum lines were investigated in 14-day competition assays against a standard competitor clone HB3, with other long-term laboratory-adapted clones showing similar or higher mean per-48-hour rates ranging from 0.98 to 1.51 relative to HB3. In contrast, thirteen Ghanaian clinical isolates cultured for close to two months prior to assay had lower rates, ranging from 0.46 to 0.76 relative to HB3. Analysing the single-genotype clinical isolates and laboratory-adapted clones, there was a highly significant correlation between the competitive rates and previously determined exponential rates (Spearmans rho = 0.95, P = 0.0003), which accounted for most of the observed variance (Pearsons r2 = 0.77, P = 0.004). Testing the effect of alternative nutritional supplementation with human serum or Albumax showed a majority of parasites had consistent competitive rates under either condition, indicating that intrinsic differences determine most variation among parasites.

Ivermectin is an important broad-spectrum anthelmintic used to treat nematode parasites including gastro-intestinal infections of humans and animals. The mode of action for Ivermectin is understood to involve activation of inhibitory glutamate-gated chloride channels (GluCls). Ivermectin has also been reported to inhibit the release of extracellular vesicles (EVs). We found that EVs are released from the whole intestine of the gastro-intestinal parasite, Ascaris suum. Proteomic analysis identified 1,574 proteins within these intestinal EVs, including 96 nematode proteins with putative immune-associated functions based on homology to proteins involved in host immune processes and 130 proteins with predicted digestive functions. Comparative analysis following ivermectin exposure revealed 38 differentially abundant proteins that included the putative immune-related proteins: transthyretin-like proteins, a small heat-shock antigen, a phospholipase A2, and the NF-{kappa}B subunit p105. Thus, ivermectin modulated the potential immune-related cargo of intestinal EVs. The ivermectin inhibition of intestinal EV release was concentration-dependent with an IC50 of 64 nM. We also identified the expression of GluCl subunit receptor genes in the Ascaris intestine. The potent inhibitory effect of ivermectin on the release of these EVs from the nematode intestine and the expression of GluCl channel subunits sheds further light on the site and mechanisms of action of this important anthelmintic.

This data paper presents a curated, georeferenced dataset of the frequencies of the two main target site mutations (V1016G and F1534C) associated with resistance to pyrethroid insecticides in Aedes albopictus in Italy. Populations were collected in 102 out 107 Italian provinces between 2023 and 2025. Specimens were sampled by members of the Mosquito Insecticide Resistance Italian Network (MosqIRIT) as part of RN2 activities within the INF-ACT project. Genotyping was performed on 3,517 individuals by specific allele-specific PCR assays. Each record includes metadata on sampling site, administrative location, developmental stage, collection method, and mutation-specific genotype frequencies. To support spatial analysis modelling effort, the dataset integrates geographic, eco-climatic, and demographic data. This resource will support mosquito control programs, pyrethroid resistance monitoring and managing, as well as ecological modelling, and is compliant with the FAIR data program.